The Latest Breaking News from Pfizer

Boosters will be offered around six months on from the previous winter dose

Over 75s and some under 12s are on the list

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Novavax says there's "substantial doubt" regarding its ability to continue, and NVAX stock crashed Wednesday.

Autonomous driving technology developer Mobileye Global rebounds after Friday's big sell-off.

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday.

Pfizer (PFE) reported record-breaking revenue and earnings for fiscal 2022. Furthermore, the combination of expected launches and additional pipeline products position the company for continued robust growth through the rest of this decade and beyond. Amid a volatile macro environment, investing in this high-value stock for the long term could…